Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Chile Exports

9th Sep 2008 07:00

RNS Number : 9848C
Beximco Pharmaceuticals Ltd
09 September 2008
 



BEXIMCO PHARMACEUTICALS LTD.

9 September 2008

Beximco Pharma commences exports to Chile

Beximco Pharmaceuticals Ltd. ("BPL" or the "Company"), the leading pharmaceutical manufacturer and the largest exporter of pharmaceutical products from Bangladesh, today announces that it has commenced exports to Chile, after receiving marketing authorization for a number of products from "Instituto de Salud Publica de Chile" (Drug Regulatory authority in Chile). With this, BPL has become the first Bangladeshi pharmaceutical company to obtain product registration in any Latin American country.

Chile is the sixth largest pharmaceutical market in Latin AmericaIn 2007, the Chilean pharmaceutical market was valued at US$1.5 billion. 

Beximco Pharma CEO Mr. Nazmul Hassan said:

"Our entry into Latin America marks another milestone in the Company's plan to become a global pharmaceutical company. With a market size of around US$40 billion and with a high growth rate, Latin America is considered as one of the biggest pharmaceutical markets and it is strategically important for us in our global expansion programBeing successful in registering our products in Chile will mark our presence in the regionWe continue to seek similar opportunities and are actively working in other Latin American countries." 

For further enquiries please contact:

 

Beximco Pharma

Nazmul Hassan, CEO

Tel: +880 2 861 9151, ext.2080

 

Libertas Capital

Aamir Quraishi / Andrew Hardy

Tel: +44 (0)20 7569 9650

 

Financial Dynamics

David Yates / Susan Quigley

Tel: +44 (0)20 7269 7169

 

Notes to Editors

About Beximco Pharmaceuticals Limited

Founded in 1976 and based in DhakaBangladesh, BPL manufactures and sells generic pharmaceutical formulation products, active pharmaceutical ingredients and intravenous fluids. The Company also manufactures and markets its own branded generics for almost all diseases. The Company also undertakes contract manufacturing for multinational pharmaceutical companies. The Company operates from a 20 acre site in Dhaka and currently employs over 2,400 staff.

The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri LankaNepalBhutanVietnamCambodia and Myanmar and in other markets overseas, principally in East Africa, Pacific Island and Central American countries and South East Asia, including Singapore and Hong Kong.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUWANRWSRKRAR

Related Shares:

Beximco Pharma
FTSE 100 Latest
Value8,474.74
Change-133.74